TG Therapeutics completes FDA filing for Roche challenger in CLLTG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab Share XTG Therapeutics completes FDA filing for Roche challenger in CLLhttps://pharmaphorum.com/news/tg-therapeutics-completes-fda-filing-for-roche-challenger-in-cll/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
AZ says Calquence is a safer drug than ImbruvicaAstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment Share XAZ says Calquence is a safer drug than Imbruvicahttps://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/
TG Therapeutics raises funds for cancer combination drugTG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month Share XTG Therapeutics raises funds for cancer combination drughttps://pharmaphorum.com/news/tg-therapeutics-set-for-upsized-ipo-to-develop-cancer-combination-drug/
CLL patients in England to get AZ’s Calquence after okay from NICENHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic Share XCLL patients in England to get AZ’s Calquence after okay from NICEhttps://pharmaphorum.com/news/cll-patients-in-england-to-get-azs-calquence-after-okay-from-nice/
TG Therapeutics challenges Roche with FDA filing for CLL drugUS biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic Share XTG Therapeutics challenges Roche with FDA filing for CLL drughttps://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/
NICE backs chemo-free CLL combination from AbbVie and RochePreviously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE Share XNICE backs chemo-free CLL combination from AbbVie and Rochehttps://pharmaphorum.com/news/nice-backs-chemo-free-cll-combination-from-abbvie-and-roche/
AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalAbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can Share XAbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalhttps://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
